Trial Profile
A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Simvastatin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 09 Feb 2024 Planned End Date changed from 29 Nov 2023 to 31 Dec 2024.
- 13 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Nov 2023.
- 23 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.